| |
| |
|
| |
|
|
|
| |
Content for site developed under the guidance of the TRACK Advisory Council.
|
|
 |
|
| |
 |
|
|
|
| |
_Antithrombotic Therapy Considerations in Special Patient Populations |
| |
|
| |
|
|
This CME activity has expired. CME credit is no longer available for this activity. However, the content will remain posted for your viewing convenience. |
ACCREDITATION STATEMENT
This activity is jointly sponsored by the Elsevier Office of CME (EOCME) and Excerpta Medica. EOCME is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education (CME) for physicians. This activity has been planned and implemented in accordance with the Essential Areas and Policies of the ACCME by the EOCME.
|
FACULTY DISCLOSURES |
|
As a sponsor accredited by the ACCME, it is the policy of the EOCME to require the disclosure of the existence of any significant financial interest or any other relationship a faculty member has with the manufacturer(s) of any commercial product discussed during his/her presentation. The faculty of this CME activity disclose the following:
| Faculty Member |
|
Manufacturer |
|
Relationship |
| Edith A. Nutescu, PharmD |
|
AstraZeneca |
|
Grants/Research Support |
|
|
Pfizer Inc., Pharmion, The sanofi-aventis Group |
|
Consultant |
|
|
AstraZeneca, The sanofi-aventis Group |
|
Speaker’s Bureau |
| Deepak L. Bhatt, MD |
|
Bristol-Myers Squibb, The sanofi-aventis Group |
|
Grants/Research Support |
| Geno J. Merli, MD |
|
AstraZeneca, The sanofi-aventis Group |
|
Grants/Research Support, Consultant, Speaker’s Bureau |
|
|
Bacchus Vascular |
|
Consultant |
|
|
Bayer Pharmaceuticals |
|
Grants/Research Support | |
|
FINANCIAL SUPPORT |
|
This CME activity is jointly sponsored by the EOCME and Excerpta Medica and supported by an unrestricted educational grant from sanofi-aventis U.S.
|
INFORMATION ON CME CREDIT |
|
The EOCME designates this educational activity for a maximum of 1.5 category 1 credits toward the American Medical Association (AMA) Physician’s Recognition Award (PRA). Each physician should claim only those hours of credit that he/she actually spent in the educational activity.
Application for CME credit has been filed with the American Academy of Family Physicians.
|
|
INTENDED AUDIENCE |
|
This activity is intended for general and specialized surgeons, critical care physicians, oncologists, general practice physicians and healthcare providers who are involved with special patient populations who may be at increased risk for thromboembolic complications. |
|
GOAL OF THE ACTIVITY |
|
To familiarize participants with antithrombotic therapy considerations – particularly in terms of LMWHs - relevant to obese patients and patients with impaired renal function, as well as to provide clinicians with practical treatment recommendations for effective thrombosis management of these difficult-to-treat patient populations. | |
|
EDUCATIONAL OBJECTIVES |
|
Upon completion of this activity, participants will be able to:
- Describe the impact of actual body weight (ABW) on dosing and anti-Xa levels
- Describe the impact of renal dysfunction levels of LMWHs on the pharmacokinetics/pharmacodynamics of LMWHs
- Recognize the pharmacokinetic/pharmacodynamic differences occurring in patients requiring antithrombotic medications who are obese or have renal impairment
- Utilize updated information as a guide for consideration of dosage adjustments compatible with physiological changes in patients who are obese or have renal impairment
- Identify the differences in monitoring antithrombotic medication effects and the rationale for outpatient antithrombosis management
This activity may contain references to off-label/unapproved uses of drugs or medical devices. Please consult the product prescribing information for full disclosure of labeled uses. |
|
CONTENT DEVELOPMENT COMMITTEE |
|
Deepak L. Bhatt, MD
Geno J. Merli, MD
Edith A. Nutescu, PharmD
Mark J. Flanick, MS |
|
HARDWARE AND SOFTWARE SPECIFICATIONS NEEDED TO VIEW SITE |
|
The program requires Windows Operating Systems (95/98, NT, 2000, ME, XP), version 5.5 browsers or higher from Microsoft or Netscape.
Certain activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Macromedia Flash, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, and Real Networks Real One Player.
|
CME PARTICIPANT DEMOGRAPHICS |
|
Antithrombotic Therapy Considerations in Special Patient Populations, An expert commentary presented by Edith A. Nutescu, PharmD, Clinical Associate Professor, Director of Antithrombosis Service, University of Illinois at Chicago College of Pharmacy and Medical Center.
Release date: March 21, 2005
Expiration date: March 21, 2007
Estimated time to complete activity: 1.5 hours |
| |
This CME course, Antithrombotic Therapy Considerations in Special Patient Populations, appears in two parts:
Please note that in order to receive full CME credit for this activity, you must participate in both courses before taking the test.
These courses are best viewed at a resolution of 800x600 pixels. Higher resolutions will result in the identical presentation appearing in a smaller viewable area. If that area is too small, resolution can be adjusted by clicking Start, Settings, Control Panel, Display, Settings, and using the slide control to adjust resolution. |
|
| |
|
|
| |
|
|